CTLA 4 News and Research

RSS

Study finds anti-correlation of KLRG1 and PD-1 expression in tumor fighting T cells

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells."

21 Jan 2025

Research sheds light on how hypoxia affects T cell function in cancer

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective.

14 Dec 2024

Australian research unlocks new path for cancer immunotherapy

Australian-led research is unlocking new ways for immunotherapy to better target cancer.

14 Dec 2024

Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.

9 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

Distinct waves of T cells generated by each dose of combination immunotherapy

A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

29 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

New research uncovers mechanisms behind heart damage from CTLA-4 blockade

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells.

7 Aug 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders.

2 Jul 2024

New research sheds light on IL-23's role in chronic inflammatory bowel diseases

Scientists at Weill Cornell Medicine discovered a previously unknown link between two key pathways that regulate the immune system in mammals - a finding that impacts our understanding of chronic inflammatory bowel diseases (IBD).

12 Jun 2024

Research reveals how Regnase-1 deficiency enhances NK cell tumor killing

Natural killer (NK) cells play a crucial role in the first line of host defense by eliminating bacteria, viruses, and mutated cells that might become cancer cells.

30 May 2024

Review highlights the rapidly evolving landscape of hepatocellular carcinoma treatment

Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms.

22 May 2024

LAG-3 protein structure may be the key to unlocking new cancer treatments

A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.

11 Mar 2024

Gut bacteria strains could be the key to predicting cancer treatment success

Researchers discovered that gut microbiota strains can predict the effectiveness and adverse effects of immune checkpoint blockade (ICB) therapy in rare cancer patients.

6 Mar 2024

Microbial signatures linked to immunotherapy response across cancers

The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.

1 Mar 2024

Novel drug combination shows promise for treating advanced skin cancers in kidney transplant recipients

People who have had a kidney transplant are at high risk for developing skin cancers. New research directed by investigators from the Johns Hopkins Kimmel Cancer Center is exploring the best combination of treatments to target skin cancers while preserving the transplanted organs.

28 Feb 2024

Study: Antibody combination shows safety and anti-tumor activity in advanced cancer patients

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.

26 Feb 2024

Comprehensive analysis of immune checkpoint inhibitors reveals endocrine toxicity patterns

Announcing a new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a challenge of immune-related adverse events (irAEs), particularly endocrine toxicity, that can severely compromise patient well-being.

21 Feb 2024